As of this week, consumers can get a generic version of Lipitor, the best-selling drug developed by Pfizer.
Heralding this fact, in the mainstream press as well as in the business press, are the kinds of praises and exultations one usually hears only on Oscar night.
Forbes.com’s Avik Roy, in his blog (The Apothecary) points to several of these http://www.forbes.com/sites/aroy/2011/11/30/lipitor-is-dead-long-live-lipitor/ .
One of the most interesting is certainly that by Paul Howard in “Medical Progress Today,” who offers a detailed accounting, and reminder, of how dramatically Lipitor has changed the nation’s cardiovascular landscape http://www.medicalprogresstoday.com/2011/11/the-end-of-the-age-of-lipitor.php.